S

Shennon Biotechnologies

Develops precision T-cell engager immunotherapies

CMC Lead – Multispecific Antibodies

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeSan Francisco, CA, USANo salary listed

About the Job

Requirements

  • A PhD in a relevant discipline, or a bachelor's or master's degree with at least 12 years in biologics CMC.
  • At least one antibody or antibody-derived protein taken from development candidate to IND with the CMC package filed, ideally a bispecific or multispecific rather than a monoclonal.
  • Direct experience selecting and managing contract development and manufacturing organizations (CDMOs), including writing requests for proposals (RFPs) and critically evaluating quotes.
  • Quality fluency sufficient to negotiate a quality agreement and make a release decision on outsourced good manufacturing practice (GMP) material.
  • Module 3 authoring or quality control (QC) experience, and sufficient regulatory fluency to defend the CMC section in an agency meeting.
  • Comfort working with CDMOs in China alongside United States and European options, and a clear view of the trade-offs.
  • Judgment on when to push a timeline and when to refuse one.

Responsibilities

  • Build an integrated CMC plan from development candidate nomination to first-in-human and own its timeline.
  • Run a competitive RFP for CDMO selection, providing the same package to prospective vendors to enable normalized quote comparison.
  • Negotiate with and manage the selected CDMO across cell line development, process development, analytical development, technology transfer, GMP drug substance and drug product, and stability.
  • Own quality for outsourced manufacture, including the CDMO quality agreement, batch record and deviation review, out-of-specification (OOS) handling, specifications, and release and disposition decisions for GMP material.
  • Own the CMC budget and forecast, evaluate CDMO quote line items, and manage the forecast against the cash plan.
  • Own the analytical and release strategy, including the cell-based potency assay.
  • Secure good laboratory practice (GLP) toxicology material and own downstream clinical supply, including labeling, packaging, comparator sourcing, and shipment to trial sites.
  • Author and quality-check Module 3, build the CMC content of the pre-IND briefing package, and participate in subsequent agency meetings.
  • Flag format-driven CMC risks early, including chain pairing, product-related species, and purification strategy, so they inform format selection.

About the Company

Shennon Biotechnologies

Develops precision T-cell engager immunotherapies

Shennon Biotechnologies develops precision immunotherapies for solid tumors, focusing on T-cell engagers (TCEs). Its discovery platform combines target discovery, ultra-high-throughput microfluidic screening, computational design, and safety prediction, with the TCELERATOR system profiling over 10 million single-cell interactions. It differentiates itself by integrating large-scale functional screening with multi-target TCE formats (trispecific, antibody-based, and TCR-based) to identify safer, more effective candidates for solid tumors. The company aims to move from platform development to development-stage execution, advancing three programs (SBT-121, SBT-201, SBT-425) and pursuing ongoing fundraising and leadership to push toward clinical development.

Company size
11-50
Company stage
Early VC
Total funding
$25M
Headquarters
San Francisco, CA
Founded
2021

Recently Posted Jobs

Explore more opportunities at Shennon Biotechnologies

See more jobs